23.94 USD
+0.03 (+0.13%)
23.93 USD
-0.01 (-0.04%)
NXGN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. NXGN has an average financial health and profitability rating. NXGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year NXGN was profitable.
- NXGN had a negative operating cash flow in the past year.
- NXGN had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years NXGN had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of -0.72%, NXGN is doing good in the industry, outperforming 78.57% of the companies in the same industry.
- NXGN has a better Return On Equity (-1.47%) than 78.57% of its industry peers.
- With a decent Return On Invested Capital value of 0.82%, NXGN is doing good in the industry, outperforming 78.57% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for NXGN is below the industry average of 6.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.72% | ||
| ROE | -1.47% | ||
| ROIC | 0.82% |
ROA(3y)0.48%
ROA(5y)1.41%
ROE(3y)0.64%
ROE(5y)2.06%
ROIC(3y)1.91%
ROIC(5y)2.95%
1.3 Margins
- Looking at the Operating Margin, with a value of 1.06%, NXGN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
- In the last couple of years the Operating Margin of NXGN has declined.
- With a Gross Margin value of 46.40%, NXGN perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
- In the last couple of years the Gross Margin of NXGN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.06% | ||
| PM (TTM) | N/A | ||
| GM | 46.4% |
OM growth 3Y-58.31%
OM growth 5Y-27.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y-2.66%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NXGN is destroying value.
- Compared to 1 year ago, NXGN has less shares outstanding
- Compared to 1 year ago, NXGN has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.59 indicates that NXGN is not in any danger for bankruptcy at the moment.
- NXGN has a Altman-Z score of 3.59. This is in the better half of the industry: NXGN outperforms 78.57% of its industry peers.
- A Debt/Equity ratio of 0.63 indicates that NXGN is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.63, NXGN is doing worse than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.59 |
ROIC/WACC0.08
WACC10.14%
2.3 Liquidity
- NXGN has a Current Ratio of 2.52. This indicates that NXGN is financially healthy and has no problem in meeting its short term obligations.
- NXGN has a Current ratio (2.52) which is comparable to the rest of the industry.
- A Quick Ratio of 2.52 indicates that NXGN has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.52, NXGN is in line with its industry, outperforming 52.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
- NXGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.33%, which is quite impressive.
- Measured over the past 5 years, NXGN shows a small growth in Earnings Per Share. The EPS has been growing by 6.96% on average per year.
- NXGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.25%.
- NXGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.23% yearly.
EPS 1Y (TTM)33.33%
EPS 3Y5.69%
EPS 5Y6.96%
EPS Q2Q%24%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y6.53%
Revenue growth 5Y4.23%
Sales Q2Q%10.65%
3.2 Future
- NXGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.15% yearly.
- NXGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.76% yearly.
EPS Next Y14.49%
EPS Next 2Y17.83%
EPS Next 3Y17.28%
EPS Next 5Y17.15%
Revenue Next Year11.2%
Revenue Next 2Y9.22%
Revenue Next 3Y8.41%
Revenue Next 5Y7.76%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 21.38, which indicates a rather expensive current valuation of NXGN.
- NXGN's Price/Earnings ratio is rather cheap when compared to the industry. NXGN is cheaper than 92.86% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.94, NXGN is valued a bit cheaper.
- A Price/Forward Earnings ratio of 17.59 indicates a rather expensive valuation of NXGN.
- NXGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. NXGN is cheaper than 92.86% of the companies in the same industry.
- NXGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.38 | ||
| Fwd PE | 17.59 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, NXGN is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 34.12 |
4.3 Compensation for Growth
- NXGN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- NXGN's earnings are expected to grow with 17.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.48
PEG (5Y)3.07
EPS Next 2Y17.83%
EPS Next 3Y17.28%
5. Dividend
5.1 Amount
- No dividends for NXGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.94
+0.03 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)10-24 2023-10-24/amc
Earnings (Next)01-22 2024-01-22/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners31.12%
Ins Owner Change0%
Market Cap1.61B
Revenue(TTM)695.05M
Net Income(TTM)-6.21M
Analysts50.77
Price Target24.41 (1.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.71
Dividend Growth(5Y)3.39%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.08%
Min EPS beat(2)6.95%
Max EPS beat(2)23.21%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-6.17%
Max EPS beat(4)23.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-2.26%
Max Revenue beat(2)0.72%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-2.26%
Max Revenue beat(4)2.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.11%
PT rev (3m)16.34%
EPS NQ rev (1m)-2.38%
EPS NQ rev (3m)-0.97%
EPS NY rev (1m)0%
EPS NY rev (3m)0.55%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.38 | ||
| Fwd PE | 17.59 | ||
| P/S | 2.31 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.8 | ||
| P/tB | 94.94 | ||
| EV/EBITDA | 34.12 |
EPS(TTM)1.12
EY4.68%
EPS(NY)1.36
Fwd EY5.68%
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS10.36
BVpS6.31
TBVpS0.25
PEG (NY)1.48
PEG (5Y)3.07
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.72% | ||
| ROE | -1.47% | ||
| ROCE | 1.04% | ||
| ROIC | 0.82% | ||
| ROICexc | 1.14% | ||
| ROICexgc | 5.45% | ||
| OM | 1.06% | ||
| PM (TTM) | N/A | ||
| GM | 46.4% | ||
| FCFM | N/A |
ROA(3y)0.48%
ROA(5y)1.41%
ROE(3y)0.64%
ROE(5y)2.06%
ROIC(3y)1.91%
ROIC(5y)2.95%
ROICexc(3y)2.27%
ROICexc(5y)3.46%
ROICexgc(3y)18.71%
ROICexgc(5y)23.54%
ROCE(3y)2.41%
ROCE(5y)3.74%
ROICexgc growth 3Y-50.16%
ROICexgc growth 5Y-31.62%
ROICexc growth 3Y-56.26%
ROICexc growth 5Y-28.38%
OM growth 3Y-58.31%
OM growth 5Y-27.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y-2.66%
F-Score2
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.98 | ||
| Cap/Depr | 95.52% | ||
| Cap/Sales | 5.14% | ||
| Interest Coverage | 1.1 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z | 3.59 |
F-Score2
WACC10.14%
ROIC/WACC0.08
Cap/Depr(3y)75.15%
Cap/Depr(5y)68.18%
Cap/Sales(3y)5.17%
Cap/Sales(5y)5.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3Y5.69%
EPS 5Y6.96%
EPS Q2Q%24%
EPS Next Y14.49%
EPS Next 2Y17.83%
EPS Next 3Y17.28%
EPS Next 5Y17.15%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y6.53%
Revenue growth 5Y4.23%
Sales Q2Q%10.65%
Revenue Next Year11.2%
Revenue Next 2Y9.22%
Revenue Next 3Y8.41%
Revenue Next 5Y7.76%
EBIT growth 1Y-70.75%
EBIT growth 3Y-55.58%
EBIT growth 5Y-24.47%
EBIT Next Year47.96%
EBIT Next 3Y27.47%
EBIT Next 5Y21.11%
FCF growth 1Y-203.01%
FCF growth 3Y-52.24%
FCF growth 5Y-32.4%
OCF growth 1Y-110.78%
OCF growth 3Y-20.1%
OCF growth 5Y-10.01%
NEXTGEN HEALTHCARE INC / NXGN FAQ
What is the fundamental rating for NXGN stock?
ChartMill assigns a fundamental rating of 4 / 10 to NXGN.
Can you provide the valuation status for NEXTGEN HEALTHCARE INC?
ChartMill assigns a valuation rating of 3 / 10 to NEXTGEN HEALTHCARE INC (NXGN). This can be considered as Overvalued.
What is the profitability of NXGN stock?
NEXTGEN HEALTHCARE INC (NXGN) has a profitability rating of 4 / 10.
What is the financial health of NEXTGEN HEALTHCARE INC (NXGN) stock?
The financial health rating of NEXTGEN HEALTHCARE INC (NXGN) is 4 / 10.
How sustainable is the dividend of NEXTGEN HEALTHCARE INC (NXGN) stock?
The dividend rating of NEXTGEN HEALTHCARE INC (NXGN) is 0 / 10 and the dividend payout ratio is 0%.